Assessment and management of B3 breast lesions with atypia: a focused review

References

• Perry N, Broeders M, de Wolf C. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition-summary document. Ann Oncol 2007;19:614–22
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO Classification of Tumours of the Breast. 4th ed. International Agency for Research on Cancer, Lyon: IARC; 2012
   Google Scholar
• de Beca FF, Rasteiro C, Correia A, et al. Improved malignancy prediction by B3 breast lesions subclassification. Ann Diagn Pathol 2013;17:434–6
   PubMed Web of Science ®Google Scholar
• Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146–51
   PubMed Web of Science ®Google Scholar
• Palli D, Rosselli del Turco M, Simoncini R, et al. Benign breast disease and breast cancer: a case-control study in a cohort in Italy. Int J Cancer 1991;47:703–6
   PubMed Web of Science ®Google Scholar
• Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997;6:297–301
   PubMed Web of Science ®Google Scholar
• Houssami N, Ciatto S, Bilous M, et al. Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3). Br J Cancer 2007;23:1253–7
   Google Scholar
• Liberman L, Drotman M, Morris EA, et al. Imaging-histologic discordance at percutaneous breast biopsy. Cancer 2000;15:2538–46
   Google Scholar
• Lee JM, Kaplan JB, Murray MP, et al. Imaging histologic discordance at MRI-guided 9-gauge vacuum-assisted breast biopsy. Am J Roentgenol 2007;189:852–9
   PubMed Web of Science ®Google Scholar
• Bianchi S, Caini S, Renne G, et al. Positive predictive value for malignancy on surgical excision of breast lesions of uncertain malignant potential (B3) diagnosed by stereotactic vacuum-assisted needle core biopsy (VANCB): a large multi-institutional study in Italy. Breast 2011;20:264–70
   PubMed Web of Science ®Google Scholar
• Forester ND, Lowes S, Mitchell E, et al. High risk (B3) breast lesions: what is the incidence of malignancy for individual lesion subtypes? A systematic review and meta-analysis. Eur J Surg Oncol 2019;45:519–27
   PubMed Web of Science ®Google Scholar
• Arpino G, Laucirica R, Fau-Elledge RM, et al. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005;20:446–57
   Google Scholar
• Parker SH, Lovin JD, Jobe WE, et al. Nonpalpable breast lesions: stereotactic automated large-core biopsies. Radiology 1991;180:403–7
   PubMed Web of Science ®Google Scholar
• Mainiero MB, Gareen IF, Bird CE, et al. Preferential use of sonographically guided biopsy to minimize patient discomfort and procedure time in a percutaneous image-guided breast biopsy program. J Ultrasound Med 2002;21:1221–6
   PubMed Web of Science ®Google Scholar
• Corben AD, Edelweiss M, Brogi E. Challenges in the interpretation of breast core biopsies. Breast J 2010;16:S5–S9
   PubMed Web of Science ®Google Scholar
• Dillon MF, Hill AD, Quinn CM, et al. The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases. Ann Surg 2005;242:701–7
   PubMed Web of Science ®Google Scholar
• Sohn V, Arthurs Z, Herbert G, et al. Atypical ductal hyperplasia: improved accuracy with the 11-gauge vacuum-assisted versus the 14-gauge core biopsy needle. Ann Surg Oncol 2007;14:2497–501
   PubMed Web of Science ®Google Scholar
• Houssami N, Ciatto S, Ellis I, et al. Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. Cancer 2007;1:487–95
   Google Scholar
• Rageth CJ, O’Flynn EA, Comstock C, et al. First International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Res Treat 2016;159:203–13
   PubMed Web of Science ®Google Scholar
• Page DL, Dupont WD, et al. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;1:2698–708
   Google Scholar
• Rakha EA, Lee AH, Jenkins JA, et al. Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Int J Cancer 2011;15:1417–24
   Google Scholar
• Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;21:229–37
   Google Scholar
• Hartmann LC, Radisky DC, Frost MH, et al. Understanding the premalignant potential of atypical hyperplasia through its natural history: a longitudinal cohort study. Cancer Prev Res 2014;7:211–17
   PubMed Web of Science ®Google Scholar
• Page DL, Schuyler PA, Dupont WD, et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003;11:125–9
   Google Scholar
• Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 2003;13:5974–9
   Google Scholar
• Jang M, Cho N, Moon WK, et al. Underestimation of atypical ductal hyperplasia at sonographically guided core biopsy of the breast. Am J Roentgenol 2008;191:1347–51
   PubMed Web of Science ®Google Scholar
• Grady I, Gorsuch H, Wilburn-Bailey S. Ultrasound-guided, vacuum-assisted, percutaneous excision of breast lesions: an accurate technique in the diagnosis of atypical ductal hyperplasia. J Am Coll Surg 2005;201:14–17
   PubMed Web of Science ®Google Scholar
• Racz JM, Degnim AC. When does atypical ductal hyperplasia require surgical excision? Surg Oncol Clin N Am 2018;27:23–32
   PubMed Web of Science ®Google Scholar
• Guidelines of the AGO breast committee: lesions of uncertain malignant potential (B3). 2016. Available from: https://www.agoonline.de/fileadmin/downloads/leitlinien/mamma/Maerz2016/en/2016E%2006_Lesions%20of%20Uncertain%20Malignant%20Potential%20%28B3%29.pdf
   Google Scholar
• Bevers TB, Helvie M, Bonaccio E, et al. Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2018;16:1362–89
   PubMed Web of Science ®Google Scholar
• Forgeard C, Benchaib M, Guerin N, et al. Is surgical biopsy mandatory in case of atypical ductal hyperplasia on 11-gauge core needle biopsy? A retrospective study of 300 patients. Am J Surg 2008;196:339–45
   PubMed Web of Science ®Google Scholar
• Haagensen CD, Lane N, Lattes R, et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978;42:737–69
   PubMed Web of Science ®Google Scholar
• Jorns J, Sabel MS, Pang JC. Lobular neoplasia: morphology and management. Arch Pathol Lab Med 2014;138:1344–9
   PubMed Web of Science ®Google Scholar
• Rosner D, Bedwani RN, Vana J, et al. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg 1980;192:139–47
   PubMed Web of Science ®Google Scholar
• Page DL, Kidd TE, Jr, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 1991;22:1232–9
   PubMed Web of Science ®Google Scholar
• Ellis IO, Humphreys S, Michell M, et al. Best Practice No 179. Guidelines for breast needle core biopsy handling and reporting in breast screening assessment. J Clin Pathol 2004;57:897–902
   PubMed Web of Science ®Google Scholar
• Morrow M, Schnitt SJ, Norton L. Current management of lesions associated with an increased risk of breast cancer. Nat Rev Clin Oncol 2015;12:227–38
   PubMed Web of Science ®Google Scholar
• Collins LC, Baer H, Tamimi RM, et al. Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health Study. Cancer 2007;15:180–7
   Google Scholar
• Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. JCO 2007;1:2671–7
   Google Scholar
• Berg WA. Image-guided breast biopsy and management of high-risk lesions. Radiol Clin North Am 2004;42:935–46
   PubMed Web of Science ®Google Scholar
• Foote FW, Stewart FW. Lobular carcinoma in situ: a rare form of mammary cancer. Am J Pathol 1941;17:491–3
   PubMedGoogle Scholar
• Rosen PP, Kosloff C, Lieberman PH, et al. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 1978;2:225–51
   PubMed Web of Science ®Google Scholar
• Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer 1996;1:1024–34
   Google Scholar
• Chuba PJ, Hamre MR, Yap J, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. JCO 2005;20:5534–41
   Google Scholar
• Hutter RV. The management of patients with lobular carcinoma in situ of the breast. Cancer 1984;1:798–802
   Google Scholar
• Powers RW, O'Brien PH, Kreutner A. Jr., Lobular carcinoma in situ. J Surg Oncol 1980;13:269–73
   PubMed Web of Science ®Google Scholar
• Li CI, Anderson BO, Daling JR, et al. Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat 2002;75:259–68
   PubMed Web of Science ®Google Scholar
• Frost AR, Tsangaris TN, Silverberg SG. Pleomorphic lobular carcinoma in situ. Pathol Case Rew 1996;1:27–30
   Google Scholar
• Wen HY, Brogi E. Lobular carcinoma in situ. Surg Pathol Clin 2018;11:123–45
   PubMedGoogle Scholar
• Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management of lobular neoplasia. J Natl Compr Cancer Netw 2006;4:511–22
   PubMedGoogle Scholar
• Collins LC. Precursor lesions of the low-grade breast neoplasia pathway. Surg Pathol Clin 2018;11:177–97
   PubMedGoogle Scholar
• Degnim AC, King TA. Surgical management of high-risk breast lesions. Surg Clin North Am 2013;93:329–40
   PubMed Web of Science ®Google Scholar
• Khoumais NA, Scaranelo AM, Moshonov H, et al. Incidence of breast cancer in patients with pure flat epithelial atypia diagnosed at core-needle biopsy of the breast. Ann Surg Oncol 2013;20:133–8
   PubMed Web of Science ®Google Scholar
• Lamb LR, Bahl M, Gadd MA, et al. Flat epithelial atypia: upgrade rates and risk-stratification approach to support informed decision making. J Am Coll Surg 2017;225:696–701
   PubMed Web of Science ®Google Scholar
• Lavoue V, Roger CM, Poilblanc M, et al. Pure flat epithelial atypia (DIN 1a) on core needle biopsy: study of 60 biopsies with follow-up surgical excision. Breast Cancer Res Treat 2011;125:121–6
   PubMed Web of Science ®Google Scholar
• Boufelli G, Giannotti MA, Ruiz CA, et al. Papillomas of the breast: factors associated with underestimation. Eur J Cancer Prev 2018;34:1304–8
   Google Scholar
• Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;20:1879–86
   Google Scholar
• Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;15:111–30
   Google Scholar
• Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 2019;21:1708–18
   PubMed Web of Science ®Google Scholar
• Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003;40:807–14
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Hurley P, Bantug E, et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013;1:4383
   Google Scholar
• Kerlikowske K, Gard CC, Tice JA, et al. Risk factors that increase risk of estrogen receptor-positive and -negative breast cancer. J Natl Cancer Inst 2016;31:109
   Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;16:1371–88
   Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA 1999;16:2189–97
   Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696–706
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Ales-Martinez JE, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;23:2381–91
   Google Scholar
• Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014;22:1041–8
   Google Scholar